Hepatitis B virus reactivation in a Juvenile Rheumatoid arthritis patient under treatment and its successful management: A complicated case

Rheumatology International

Volumn 33, Issue 5, 2013, Pages 1345-1349

  Durmus, Oguz ^a   Tekin, Levent ^a   Carli, Alparslan Bayram ^a   Cakar, Engin ^a   Acar, Ali ^a   Ulcay, Asim ^b   Dincer, Umit ^a   Kiralp, Mehmet Zeki ^a  

^a GATA HAYDARPASA TRAINING HOSPITAL   (Turkey)

^b KASIMPASA MILITARY HOSPITAL   (Turkey)

Author keywords

Biological agent; DMARDs; Hepatitis B virus; Juvenile Rheumatoid Arthritis

Indexed keywords

ADALIMUMAB; DEFLAZACORT; ENTECAVIR; ETANERCEPT; HEPATITIS B SURFACE ANTIGEN; IMMUNOSUPPRESSIVE AGENT; LEFLUNOMIDE; LIVER ENZYME; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE;

ADULT; ANKLE PAIN; ANTIVIRAL THERAPY; ARTHRALGIA; ARTICLE; BONE SCINTISCANNING; CASE REPORT; CORTICOSTEROID THERAPY; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HYPERTRANSAMINASEMIA; IMMUNOSUPPRESSIVE TREATMENT; JOINT SWELLING; JUVENILE RHEUMATOID ARTHRITIS; LIVER FUNCTION TEST; LIVER INJURY; MALE; MEDICAL HISTORY; MORBIDITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOPOROSIS; PAIN; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SACROILIAC JOINT; SACROILIITIS; UVEITIS; VIRUS LOAD; VIRUS REACTIVATION; WRIST;

ANTIVIRAL AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; BIOLOGICAL MARKERS; DRUG SUBSTITUTION; GUANINE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; MAGNETIC RESONANCE IMAGING; MALE; OPPORTUNISTIC INFECTIONS; RECEPTORS, TUMOR NECROSIS FACTOR; TIME FACTORS; TREATMENT OUTCOME; VIRUS ACTIVATION; YOUNG ADULT;

EID: 84878012871     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-011-2244-9     Document Type: Article

References (24)

1. Hinks A, Eyre S, Ke X, Barton A, Martin P, Flynn E, Packham Jon, Childhood Arthritis Prospective Study (CAPS), UKRAG Consortium, BSPAR Study Group, Worthington J, Thomson W (2010) Overlap of disease susceptibility loci for rheumatoid arthritis and juvenile idiopathic arthritis. Ann Rheum Dis 69:1049-1053. doi: 10.1136/ard.2009.110650
2. Prahalad S (2004) Genetics of juvenile idiopathic arthritis: an update. Curr Opin Rheumatol 16:588-594
3. Cassidy JT, Levinson JE, Bass JC, Baum J, Brewer EJ, Fink CW, Hanson V, Jacobs JC, Masi AT, Schaller JG, Fries JF, Mcshane D, Young D (1986) A study of classification criteria for a diagnosis of juvenile rheumatoid arthritis. Arthritis Rheum 29:274-281
4. Schaller JG (1984) Chronic arthritis in children juvenile rheumatoid arthritis. Clin Orthop Rel Res 182:79-89
5. Flatø B, Smerdel A, Johnston V, Lien G, Dale K, Vinje O, Egeland T, Sørskaar D, Førre Ø (2002) The influence of patient characteristics, disease variables, and HLA alleles on the development of radiographically evident sacroiliitis in juvenile idiopathic arthritis. Arthritis Rheum 46:986-994. doi: 10.1002/art.10146
6. Capkin E, Karkucak M, Yilmaz G, Aydin K, Tosun M (2007) A case report of hepatitis B carriage in a patient with ankylosing spondylitis improving following infliximab treatment and a review of the literature. J Back Musculoskelet 20:123-125
7. Giannini EH, Ilowite NT, Lovell DJ, Wallace CA, Rabinovich CE, Reiff A, Higgins G, Gottlieb B, Singer NG, Pediatric Rheumatology Collaborative Study Group, Chon Y, Lin SL, Baumgartner SW (2009) Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum 60:2794-2804. doi: 10.1002/art.24777
8. Kalyoncu U, Yonem O, Calguneri M, Ersoy O, Karadag O, Akdogan A, Bilgen SA, Kiraz S, Ertenli I, Bayraktar O (2009) Prophylactic use of lamivudine with chronic immunsuppresive therapy for rheumatologic disorders. Rheumatol Int 29:777-780. doi: 10.1007/s00296-008-0790-6
9. Yeo W, Chan PKS, Zhong S, Ho WM, Steinberg JL, Tam JS, Hui P, Leung NWY, Zee B, Johnson PJ (2000) Frequency of Hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patinets with identification of risk factors. J Med Virol 62:299-307. doi: 10.1002/1096-9071(200011)62:3<299:AID-JMV1>3.0.CO;2-0
10. Calabrese LH, Zein NN, Vassilopoulos D (2006) Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies. Ann Rheum Dis 65:983-989. doi: 10.1136/ard.2005. 043257
11. Lacaille D, Guh DP, Abrahamowicz M, Anis AH, Esdaile JM (2008) Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis. Arthritis Rheum 59:1074-1081. doi: 10.1002/art.23913
12. Goldenberg MM (1999) Leflunomide, a novel immunomodulator for the treatment of active rheumatoid arthritis. Clin Ther 21:1837-1852. doi: 10.1016/S0149-2918(00)86732-6
13. Curtis JR, Beukelman T, Onofrei A, Cassell S, Greenberg JD, Kavanaugh A, Reed G, Strand V, Kremer JM (2010) Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide. Ann Rheum Dis 69:43-47. doi: 10.1136/ard.2008.101378
14. Lubel JS, Testro AG, Angus PW (2007) Hepatitis B virus reactivation following immunsuppressive therapy: guidelines for prevention and management. Int Med J 37:705-712. doi: 10.1111/j.1445-5994.2007.01479.x
15. Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, Stein LD, Gedalia A, Ilowite NT, Wallace CA, Whitmore J, Finck BK (2000) Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 342:763-769
16. Inanç N, Direskeneli H (2006) Serious infections undr treatment with TNF-α antagonsits compared to traditional DMARDs in patients with rheumatoid arthritis. Rheumatol Int 27:67-71. doi: 10.1007/s00296-006-0165-9
17. Sakellariou GT, Chatzigiannis I (2007) Long-term anti-TNF alpha therapy for ankylosing spondylitis in two patients with chronic HBV infection. Clin Rheumatol 26:950-952. doi: 10.1007/s10067-006-0392-1
18. Chung SJ, Kim JK, Park MC, Park YB, Lee SK (2009) Reactivation of hepatitis B viral infection in inactive HbsAg carriers following anti-tumor necrosis factor-alpha terapy. J Rheumatol 36:2416-2420. doi: 10.3899/jrheum.081324
19. Thiele DL (2007) Is anti tnf therapy safe in patients with rheumatic disease who also have concurrent B or C hepatitis? Nat Rev Rheumatol 3:130-131. doi: 10.1038/ncprheum0403
20. Orenstein R, Matteson EL (2007) Opportunistic infections associated with TNF-a treatment. Future Rheumatol 2:567-576. doi: 10.2217/17460816.2.6.567
21. Nathan DM, Angus PW, Gibson PR (2006) Hepatitis B and C virus infections and anti-tumor necrosis factor-a therapy: guidelines for clinical approach. J Gastroenterol Hepatol 21:1366-1371. doi: 10.1111/j.1440-1746.2006.04559.x
22. Charpin C, Guis S, Colson P, Borentain P, Mattéi JP, Alcaraz P, Balandraud N, Thomachot B, Roudier J, Gérolami R (2009) Safety of TNF-blocking agents in rheumatic patients with serology suggesting past hepatitis B state: results from a cohort of 21 patients. Arthritis Res Ther 11:1-5. doi: 10.1186/ar2868
23. Tsang SWC, Chan HLY, Leung NWY, Chau TN, Lai ST, Chan FKL, Sung JJY (2001) Lamivudine treatment for fulminant hepatic failure due to acute exacerbation of chronic hepatitis B infection. Aliment Pharmacol Ther 15:1737-1744. doi: 10.1046/j.1365-2036.2001.01107.x
24. Brost S, Schnitzler P, Stremmel W, Eisenbach C (2010) Entecavir as treatment for reactivation of hepatitis B in immunosuppressed patients. World J Gastroenterol 16:5447-5451. doi: 10.3748/wjg.v16.i43.5447